Individualized Dosing of Therapeutic Monoclonal Antibodies—a Changing Treatment Paradigm?

Identification of Peptide Mimotope Ligands for Natalizumab

A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma

A general process for the development of peptide-based immunoassays for monoclonal antibodies